Joerg Herrmann MDProfessor of Medicine, Mayo Graduate School of Medicine, Rochester, Minnesota
Dr. Joerg Herrmann received his medical training at Ruhr University, Bochum, Germany, and completed his internship in internal medicine at the University Clinic in Essen. Following a postdoctoral research fellowship, he pursued the clinician–investigator track in internal medicine-cardiology, and further training in interventional cardiology at the Mayo Clinic, Rochester, Minnesota. He then joined the staff of the Department of Cardiovascular Diseases at the Mayo Clinic, Rochester. Currently he is an Associate Professor of Medicine at the Mayo Graduate School of Medicine and serves as the director of the Cardio-Oncology Clinic and the research director of the Ischemic Heart Disease program.
Dr. Herrmann has been receiving NIH research funding, serves as a reviewer for over 30 journals, including all major cardiovascular journals. He is also a contributor to Braunwald’s Heart Disease, the associated editor of Trends in Cardiovascular Medicine, and is the editor of the textbook Clinical Cardio-Oncology.
His main research interests are cardio-oncology, cardiac biomarkers, periprocedural myocardial infarction, atherosclerosis, and vascular biology.
Dr. Joerg Herrmann participated in the 2014 and 2016 Ponatinib in CML Cardio-Oncology Advisory Board meeting organized by ARIAD Pharmaceuticals, the 2016 Carfilzomib Advisory Board meeting organized by Amgen and is a member of the Institute for Cardio-Oncology advisory panel sponsored by Bristol-Myers Squib.
Recent Contributions to PracticeUpdate:
- Cerebral Protection Device Reduces Brain Injury Risk in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement
- New Study Evaluates the Safety and Efficacy of Biodegradable Polymer-Coated Sirolimus-Eluting Stents in Patients With Coronary Artery Disease
- First of Its Kind Study Compares Outcomes of Fractional Flow Reserve-Guided and Angiography-Guided Provisional Side Branch Stenting
- Randomized Study Demonstrates the Superiority of Laser Atherectomy for Treatment of In-Stent Restenosis in Patients With Femoropopliteal Peripheral Artery Disease
- New Study Examines the Optimal Duration Time of Dual Anti-Platelet Therapy in Patients With Second-Generation Drug-Eluting Stents
- Extended Follow-Up of Multicenter Trial Demonstrates Continued Superiority of Bivalirudin to Heparin With and Without Glycoprotein IIb/IIIa Inhibition in Patients With Acute Myocardial Infarction
- New Study Evaluates “Triple Therapy” Regimens After Drug-Eluting Stenting in Patients Requiring Oral Anticoagulation
- Large Randomized Trial Compares Use of Vascular Closure Devices to Manual Compression in Patients Undergoing Transfemoral Coronary Angiography
- Fractional Flow Reserve–Guided PCI for Stable CAD
- Fractional Flow Reserve vs Angiography in Guiding Management in NSTEMI